Set to benefit from limited competition in near term

The stock of Aurobindo Pharma surged as much as 8 per cent to Rs 795 in early trades today. This was thanks to the company receiving final approval to manufacture a limited competition high-margin generic drug in the US. Aurobindo Pharma has received final approval from the US Food & Drug Administration (US FDA) to manufacture the tablet version of 800mg Sevelamer Carbonate. This is prescr...